Merck's Investigational Activin Signaling Inhibitor Sotatercept Improved Six-Minute Walk Distance by 40.8 Meters at Week 24 Versus Placebo in Adults with Pulmonary Arterial Hypertension on Background Therapy

Sotatercept demonstrated statistically significant improvements in 8 of 9 secondary measures, including reduction in risk of clinical worsening or deathResults presented today at ACC.23/WCC and published in The New England Journal of MedicineRAHWAY, N.J.--(BUSINESS WIRE)--$MRK #MRK--Merck (NYSE: MRK), known as MSD o...

Related Keywords

United States ,Germany ,France ,Hannover ,Niedersachsen ,Canada ,French ,Julie Cunningham ,Marius Hoeper ,Peter Dannenbaum ,Damini Chokshi ,Instagram ,Linkedin ,Merck Research Laboratories ,Twitter ,Hannover Medical School ,Drug Administration ,Statement Of Merck Co Inc ,Exchange Commission ,Merck Co Inc ,Youtube ,Facebook ,European Medicines Agency ,Bristol Myers Squibb ,Acceleron Pharma Inc ,New England Journal ,Merck Research ,Physical Impacts ,Cardiopulmonary Symptoms ,Emotional Impacts ,Breakthrough Therapy Designation ,Orphan Drug ,Priority Medicines ,Acceleron Pharma ,Bristol Myers ,Looking Statement ,Securities Litigation Reform Act ,Annual Report ,